Lets try and extend this discussion a bit Redbar from a couple of points you have made.
The FDA panel told RAP it wanted to see a US double blind clinical trial that produced statistically significant results.
For the benefit of the forum would you like to offer an opinion about:
Have a crack if it takes your fancy and we can see where the discussion heads.
- Why did the FDA panel want to see statistically significant results?
- What statistically significant results (if any) were produced from the US trial?
- Forums
- ASX - By Stock
- RAP
- Ann: ResApp Submits De Novo Application to the FDA
Ann: ResApp Submits De Novo Application to the FDA, page-78
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
The Watchlist
CC9
CHARIOT CORPORATION LTD
MD - Shanthar Pathmanathan, Geologist - David Trabert
MD - Shanthar Pathmanathan
Geologist - David Trabert
SPONSORED BY The Market Online